Biomarker ID | 827 |
PMID | 22146597 |
Year | 2011 |
Biomarker | Auto-antibody signature (TARDBP, TLN1, PARK7, LEDGF/ PSIP1, and CALD1) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Differentially Expressed |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(TLN1):-Collagen binding in corneal epithelia mediated by Erk and PI-3 Kinase,Mammalian calpain regulation of cell motility,Nectin adhesion pathway,Muscle contraction,Platelet aggregation (plug formation) |
Experiment | prostate cancer Vs benign prostatic hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | Prostate cancer patient serum samples (n=41) and BPH patient samples without the diagnosis of cancer (n=39) were obtained |
Senstivity | 95% |
Specificity | 80% |
AUC | 0.95 |
Accuracy | NA |
Level Of Significance | p< 0.05 |
Method Used | BCA Protein Assay |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | TARDBP, TLN1, PARK7, PSIP1, CALD1 |